In the present study we showed that PNPLA3 and TM6SF2 gene polymorphisms significantly increased the risk of advanced fibrosis in patients with NASH, while more importantly, IR increased the risk of advanced liver fibrosis in non-diabetic patients. Here, TM6SF2 is linked to metabolic dysfunction-associated steatohepatitis.